Wednesday, February 14, 2018

US FDA News: FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint

FDA approves Erleada (apalutamide), first treatment for non-metastatic, castration-resistant prostate cancer
Read more: FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint